Claims for Patent: 10,543,179

Summary for Patent: 10,543,179

Title:	Dosage regimen of an S1P receptor modulator
Abstract:	The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.
Inventor(s):	Boulton; Craig (Horsham, GB), Burtin; Pascale (Huningue, FR), David; Olivier (Mulhouse, FR), de Vera; Ana (Basel, CH), Dumortier; Thomas (Basel, CH), Hunt; Irene (Basel, CH), Schmouder; Robert (Berkeley Heights, NJ), Collins; William C. (Basel, CH)
Assignee:
Application Number:	15/986,992
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,543,179
Patent Claims:	1. A method for treating relapsing remitting multiple sclerosis in a patient in need thereof, the method comprising: (a) identifying a patient at risk of contracting infection caused by varicella zoster virus by testing said patient for a history of infection caused by varicella zoster virus, (b) vaccinating the patient at risk of contracting infection caused by varicella zoster virus, and (c) administering orally fingolimod or a pharmaceutically acceptable salt thereof to said patient at a daily dosage of 0.5 mg, thereby limiting the risk of infection caused by varicella zoster virus. 2. The method according to claim 1, wherein treating comprises reducing the frequency of clinical exacerbations. 3. The method according to claim 1, wherein fingolimod is administered as a hydrochloride salt. 4. The method according to claim 1, wherein the infection is chickenpox.